NPH-201
Generalized Anxiety Disorder (GAD)
Pre-clinicalLead Optimization
Key Facts
Indication
Generalized Anxiety Disorder (GAD)
Phase
Pre-clinical
Status
Lead Optimization
Company
About Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to addressing the significant unmet medical needs in psychiatry and neurology by advancing a pipeline of innovative CNS therapeutics. Its lead candidate, NPH-101, is a novel rapid-acting antidepressant in Phase 2 development for major depressive disorder. The company's strategy is built on a deep understanding of neurocircuitry and a platform designed to identify compounds with superior efficacy and tolerability compared to existing treatments.
View full company profileTherapeutic Areas
Other Generalized Anxiety Disorder (GAD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BHV-7000 (Kv7.2/3 opener) | Biohaven | Phase 2 |
| GRX-917 (Deuterated Etifoxine) | atai Life Sciences | Phase 1 |
| MW-401 | MindWalk Holdings | Pre-clinical |